Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia

Maynika V. Rastogi, Linda Stork, Brian Druker, Carolyn Blasdel, Thuan Nguyen, Bruce Boston

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Imatinib mesylate, a tyrosine kinase inhibitor, is used in the treatment of chronic myelogeneous leukemia (CML). Given its ease of administration and manageable side effects in adults, imatinib mesylate was introduced as therapy for pediatric CML. Recently published case reports describe growth deceleration in children treated with imatinib. This study details the growth phenotype of seven pediatric patients maintained in remission on imatnib mesylate over an extended period of time. Procedure: This study is a retrospective chart review of pediatric patients with CML at Oregon Health & Science University treated with imatinib. Height, weight, and body mass index (BMI) measurements were collected before and during treatment. Median standard deviation scores (SDS) were analyzed by Wilcoxon Rank-Sum test and Wilcoxon signed rank cohort analysis. Results: Individual patient analysis demonstrated five of seven subjects with a statistically significant decrease in height SDS pre versus during treatment. The whole group analysis showed a trend to significance for difference in median height SDS pre and during treatment (P=0.078). Bone age was delayed in all four patients in whom bone ages were obtained. IGF-1, IGFBP-3, and thyroid levels during treatment were normal. Four patients experienced an improvement in height SDS during puberty. However, three patients approaching near final adult height failed to achieve genetic height potential determined by mid-parental target height. Conclusion: Growth in children with CML appears to be adversely impacted by imatinib therapy. BMI and IGF-1/IGFBP-3 are maintained during treatment, suggesting a direct effect of imatinib on the growth plate.

Original languageEnglish (US)
Pages (from-to)840-845
Number of pages6
JournalPediatric Blood and Cancer
Volume59
Issue number5
DOIs
StatePublished - Nov 2012

Fingerprint

Deceleration
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pediatrics
Growth
Leukemia
Insulin-Like Growth Factor Binding Protein 3
Therapeutics
Nonparametric Statistics
Insulin-Like Growth Factor I
Body Mass Index
Bone and Bones
Mesylates
Growth Plate
Imatinib Mesylate
Puberty
Protein-Tyrosine Kinases
Thyroid Gland
Cohort Studies
Phenotype
Weights and Measures

Keywords

  • Children
  • Growth
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. / Rastogi, Maynika V.; Stork, Linda; Druker, Brian; Blasdel, Carolyn; Nguyen, Thuan; Boston, Bruce.

In: Pediatric Blood and Cancer, Vol. 59, No. 5, 11.2012, p. 840-845.

Research output: Contribution to journalArticle

@article{f8c7e413aba94894a3127a9524850b81,
title = "Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia",
abstract = "Background: Imatinib mesylate, a tyrosine kinase inhibitor, is used in the treatment of chronic myelogeneous leukemia (CML). Given its ease of administration and manageable side effects in adults, imatinib mesylate was introduced as therapy for pediatric CML. Recently published case reports describe growth deceleration in children treated with imatinib. This study details the growth phenotype of seven pediatric patients maintained in remission on imatnib mesylate over an extended period of time. Procedure: This study is a retrospective chart review of pediatric patients with CML at Oregon Health & Science University treated with imatinib. Height, weight, and body mass index (BMI) measurements were collected before and during treatment. Median standard deviation scores (SDS) were analyzed by Wilcoxon Rank-Sum test and Wilcoxon signed rank cohort analysis. Results: Individual patient analysis demonstrated five of seven subjects with a statistically significant decrease in height SDS pre versus during treatment. The whole group analysis showed a trend to significance for difference in median height SDS pre and during treatment (P=0.078). Bone age was delayed in all four patients in whom bone ages were obtained. IGF-1, IGFBP-3, and thyroid levels during treatment were normal. Four patients experienced an improvement in height SDS during puberty. However, three patients approaching near final adult height failed to achieve genetic height potential determined by mid-parental target height. Conclusion: Growth in children with CML appears to be adversely impacted by imatinib therapy. BMI and IGF-1/IGFBP-3 are maintained during treatment, suggesting a direct effect of imatinib on the growth plate.",
keywords = "Children, Growth, Tyrosine kinase inhibitors",
author = "Rastogi, {Maynika V.} and Linda Stork and Brian Druker and Carolyn Blasdel and Thuan Nguyen and Bruce Boston",
year = "2012",
month = "11",
doi = "10.1002/pbc.24121",
language = "English (US)",
volume = "59",
pages = "840--845",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia

AU - Rastogi, Maynika V.

AU - Stork, Linda

AU - Druker, Brian

AU - Blasdel, Carolyn

AU - Nguyen, Thuan

AU - Boston, Bruce

PY - 2012/11

Y1 - 2012/11

N2 - Background: Imatinib mesylate, a tyrosine kinase inhibitor, is used in the treatment of chronic myelogeneous leukemia (CML). Given its ease of administration and manageable side effects in adults, imatinib mesylate was introduced as therapy for pediatric CML. Recently published case reports describe growth deceleration in children treated with imatinib. This study details the growth phenotype of seven pediatric patients maintained in remission on imatnib mesylate over an extended period of time. Procedure: This study is a retrospective chart review of pediatric patients with CML at Oregon Health & Science University treated with imatinib. Height, weight, and body mass index (BMI) measurements were collected before and during treatment. Median standard deviation scores (SDS) were analyzed by Wilcoxon Rank-Sum test and Wilcoxon signed rank cohort analysis. Results: Individual patient analysis demonstrated five of seven subjects with a statistically significant decrease in height SDS pre versus during treatment. The whole group analysis showed a trend to significance for difference in median height SDS pre and during treatment (P=0.078). Bone age was delayed in all four patients in whom bone ages were obtained. IGF-1, IGFBP-3, and thyroid levels during treatment were normal. Four patients experienced an improvement in height SDS during puberty. However, three patients approaching near final adult height failed to achieve genetic height potential determined by mid-parental target height. Conclusion: Growth in children with CML appears to be adversely impacted by imatinib therapy. BMI and IGF-1/IGFBP-3 are maintained during treatment, suggesting a direct effect of imatinib on the growth plate.

AB - Background: Imatinib mesylate, a tyrosine kinase inhibitor, is used in the treatment of chronic myelogeneous leukemia (CML). Given its ease of administration and manageable side effects in adults, imatinib mesylate was introduced as therapy for pediatric CML. Recently published case reports describe growth deceleration in children treated with imatinib. This study details the growth phenotype of seven pediatric patients maintained in remission on imatnib mesylate over an extended period of time. Procedure: This study is a retrospective chart review of pediatric patients with CML at Oregon Health & Science University treated with imatinib. Height, weight, and body mass index (BMI) measurements were collected before and during treatment. Median standard deviation scores (SDS) were analyzed by Wilcoxon Rank-Sum test and Wilcoxon signed rank cohort analysis. Results: Individual patient analysis demonstrated five of seven subjects with a statistically significant decrease in height SDS pre versus during treatment. The whole group analysis showed a trend to significance for difference in median height SDS pre and during treatment (P=0.078). Bone age was delayed in all four patients in whom bone ages were obtained. IGF-1, IGFBP-3, and thyroid levels during treatment were normal. Four patients experienced an improvement in height SDS during puberty. However, three patients approaching near final adult height failed to achieve genetic height potential determined by mid-parental target height. Conclusion: Growth in children with CML appears to be adversely impacted by imatinib therapy. BMI and IGF-1/IGFBP-3 are maintained during treatment, suggesting a direct effect of imatinib on the growth plate.

KW - Children

KW - Growth

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84866167173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866167173&partnerID=8YFLogxK

U2 - 10.1002/pbc.24121

DO - 10.1002/pbc.24121

M3 - Article

C2 - 22378641

AN - SCOPUS:84866167173

VL - 59

SP - 840

EP - 845

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -